DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $452,286 | +3.4% | 1,823 | 0.0% | 0.01% | +16.7% |
Q2 2023 | $437,520 | -4.8% | 1,823 | 0.0% | 0.01% | -14.3% |
Q1 2023 | $459,469 | -5.0% | 1,823 | 0.0% | 0.01% | -12.5% |
Q4 2022 | $483,861 | +2.7% | 1,823 | 0.0% | 0.01% | +14.3% |
Q3 2022 | $471,000 | +1.9% | 1,823 | 0.0% | 0.01% | +16.7% |
Q2 2022 | $462,000 | -13.6% | 1,823 | 0.0% | 0.01% | +20.0% |
Q1 2022 | $535,000 | -10.8% | 1,823 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $600,000 | +8.1% | 1,823 | 0.0% | 0.01% | 0.0% |
Q3 2021 | $555,000 | +10.1% | 1,823 | -2.9% | 0.01% | +25.0% |
Q2 2021 | $504,000 | +19.4% | 1,877 | 0.0% | 0.00% | +33.3% |
Q1 2021 | $422,000 | +1.2% | 1,877 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $417,000 | +3.2% | 1,877 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $404,000 | +18.1% | 1,877 | -2.9% | 0.00% | 0.0% |
Q2 2020 | $342,000 | +27.6% | 1,933 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $268,000 | -9.8% | 1,933 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $297,000 | -1.3% | 1,933 | -7.2% | 0.00% | 0.0% |
Q3 2019 | $301,000 | -0.7% | 2,083 | -1.9% | 0.00% | 0.0% |
Q2 2019 | $303,000 | +5.9% | 2,123 | -2.1% | 0.00% | 0.0% |
Q1 2019 | $286,000 | +27.7% | 2,168 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $224,000 | -5.1% | 2,168 | 0.0% | 0.00% | +50.0% |
Q3 2018 | $236,000 | +3.5% | 2,168 | -6.3% | 0.00% | 0.0% |
Q2 2018 | $228,000 | -37.7% | 2,313 | -38.2% | 0.00% | -50.0% |
Q1 2018 | $366,000 | +1.4% | 3,740 | -3.9% | 0.00% | 0.0% |
Q4 2017 | $361,000 | +8.1% | 3,891 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $334,000 | +0.9% | 3,891 | -0.8% | 0.00% | 0.0% |
Q2 2017 | $331,000 | -2.1% | 3,921 | -0.6% | 0.00% | -20.0% |
Q1 2017 | $338,000 | +10.8% | 3,946 | +0.8% | 0.01% | +25.0% |
Q4 2016 | $305,000 | -0.7% | 3,914 | 0.0% | 0.00% | -20.0% |
Q3 2016 | $307,000 | -22.3% | 3,914 | 0.0% | 0.01% | -16.7% |
Q2 2016 | $395,000 | -2.7% | 3,914 | -8.6% | 0.01% | -14.3% |
Q1 2016 | $406,000 | -0.2% | 4,284 | -2.3% | 0.01% | +16.7% |
Q4 2015 | $407,000 | +18.0% | 4,384 | +8.3% | 0.01% | 0.0% |
Q3 2015 | $345,000 | -5.0% | 4,048 | -4.7% | 0.01% | 0.0% |
Q2 2015 | $363,000 | -37.1% | 4,246 | -37.5% | 0.01% | -40.0% |
Q1 2015 | $577,000 | -3.8% | 6,799 | -2.9% | 0.01% | 0.0% |
Q4 2014 | $600,000 | -36.6% | 7,001 | -43.8% | 0.01% | -41.2% |
Q3 2014 | $947,000 | -14.1% | 12,461 | -11.0% | 0.02% | -5.6% |
Q2 2014 | $1,103,000 | +5.9% | 14,004 | +0.8% | 0.02% | +5.9% |
Q1 2014 | $1,042,000 | -2.9% | 13,899 | 0.0% | 0.02% | -5.6% |
Q4 2013 | $1,073,000 | +2.5% | 13,899 | -8.0% | 0.02% | 0.0% |
Q3 2013 | $1,047,000 | +298.1% | 15,104 | +263.1% | 0.02% | +200.0% |
Q2 2013 | $263,000 | – | 4,160 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |